How do we as an industry generate medical evidence that’s not only meaningful in the quest for regulatory approval, but compelling enough to also support timely reimbursement, clinical adoption and access?
We’re convened an expert panel discuss the role of ‘Integrated Evidence’ approaches to bridge the persistent regulatory and payer gap, and help leading pharmaceutical companies align R&D and commercial objectives.
‘The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape’ offers diverse perspectives from leaders in medical affairs, real-world data, HEOR, market access and clinical development on the potential of this approach to meet the needs of multiple stakeholders – regulators, payers, clinicians and patients, and move beyond isolated findings toward a more holistic understanding of therapeutic impact. We asked our panelists to share obstacles they’ve encountered to adopting these strategies and practical steps you can take to encourage cross-functional collaboration.
Who should watch
Pharmaceutical and biotech leaders working cross functionally to align medical evidence generation strategies to both research & development and commercial objectives including:
- Medical Affairs
- Health Economics & Outcomes Research (HEOR)
- Real world data and real world evidence
- Value & market access
- Drug development strategy
- Modeling and simulation
